100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
NEW YORK, Jan. 20, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of MannKind Corporation (“MannKind” or the “Company”) (Nasdaq:MNKD) between August 10, 2015 and January 5, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired MannKind securities between August 10, 2015 and January 5, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
